Evidence Hub

A case of advanced gastric cancer exhibiting pathological complete response after neoadjuvant chemotherapy

Taniguchi M, Watanabe Y, Shirakawa M, Nakano H, Endo W, Hamano R, Tsujie M, Yano H

Gan to kagaku ryoho. Cancer & chemotherapy, 2013

Abstract

A 77-year-old woman diagnosed as having advanced gastric cancer with para-aortic lymph node metastasis received neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1. After 2 courses of chemotherapy, distal gastrectomy with D2 lymphadenectomy was performed. There were no viable cancer cells in the primary lesion and lymph nodes. Currently, the patient is visiting our hospital for treatment with S-1 as adjuvant chemotherapy, and shows no signs of recurrence.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free